BIOCYTOGEN PHARMA. H YC1 (I54) — Capital Reinvestment Ratio
BIOCYTOGEN PHARMA. H YC1 (I54) has a Capital Reinvestment Ratio of 0.24x as of December 2025, meaning it reinvests 0% of its operating cash flow (€370.25 Million) in capital expenditures (€87.82 Million). Check I54 tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
BIOCYTOGEN PHARMA. H YC1 Capital Reinvestment Ratio (2024–2025)
This chart tracks BIOCYTOGEN PHARMA. H YC1's Capital Reinvestment Ratio across 2 annual periods. For the full cash flow conversion analysis, see I54 cash flow conversion.
Annual Capital Reinvestment Ratio for BIOCYTOGEN PHARMA. H YC1 (2024–2025)
Year-by-year Capital Reinvestment Ratio for BIOCYTOGEN PHARMA. H YC1 from 2024 to 2025. See BIOCYTOGEN PHARMA. H YC1 free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
| Year | Reinvestment Ratio | Operating CF (EUR) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2025 | 0.24x | €370.25 Million | €87.82 Million | ▲ +34.9% |
| 2024 | 0.18x | €211.25 Million | €37.13 Million | — |